

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

VERNAKALANT FOR THE RAPID CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION TO SINUS RHYTHM, NICE TA675, FEBRUARY 2021 (TERMINATED APPRAISAL)

BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR SECONDARY CARE

Mid and South Essex CCGs do not support the prescribing of vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in accordance with local recommendations for all drugs with a terminated NICE technology appraisal.

[NICE TA675](#) guidance:

NICE is unable to make a recommendation on vernakalant (Brinavess®) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This is because Correvio Ltd did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA675: Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm: https://www.nice.org.uk/guidance/ta675
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	May 2021; May 2021
Review Date	May 2026 or sooner if subject to any new updates nationally